Cambridge Healthtech Institute’s 5th Annual

Gene Therapy Manufacturing

Scaling up and Supplying Vector-Based Gene Therapies

August 27-28, 2020


Cambridge Healthtech Institute’s Gene Therapy Manufacturing meeting tackles the practical challenges facing the process development, scale-up and production of viral vector-based gene therapies, tackling key topics such as AAV, lentivirus, and retrovirus upstream and downstream process development, scale-up, viral clearance, and viral vector supply for clinical and commercial manufacturing.


Cover will include, but is not limited to:

  • Production strategies for commercializing gene therapies
  • Strategies to optimize AAV production
  • Strategies to optimize lentiviral production
  • New technologies - adherent and suspension-based platforms
  • Bioreactors
  • Raw and ancillary materials
  • Critical quality attributes
  • Facility design
  • Manufacturing strategies and predicting patient populations
  • Formulation, stability, and delivery


* The program is subject to change without notice, due to unforeseen reason.

Premier Sponsors: